Cargando…

Cancer Treatment-Related Cardiovascular Toxicity in Gynecologic Malignancies: JACC: CardioOncology State-of-the-Art Review

Improvements in early detection and treatment of gynecologic malignancies have led to an increasing number of survivors who are at risk of long-term cardiac complications from cancer treatment. Multimodality therapies for gynecologic malignancies, including conventional chemotherapy, targeted therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Parashar, Susmita, Akhter, Nausheen, Paplomata, Elisavet, Elgendy, Islam Y., Upadhyaya, Deepa, Scherrer-Crosbie, Marielle, Okwuosa, Tochukwu M., Sanghani, Rupa M., Chalas, Eva, Lindley, Kathryn J., Dent, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152205/
https://www.ncbi.nlm.nih.gov/pubmed/37144116
http://dx.doi.org/10.1016/j.jaccao.2023.02.002
_version_ 1785035704854642688
author Parashar, Susmita
Akhter, Nausheen
Paplomata, Elisavet
Elgendy, Islam Y.
Upadhyaya, Deepa
Scherrer-Crosbie, Marielle
Okwuosa, Tochukwu M.
Sanghani, Rupa M.
Chalas, Eva
Lindley, Kathryn J.
Dent, Susan
author_facet Parashar, Susmita
Akhter, Nausheen
Paplomata, Elisavet
Elgendy, Islam Y.
Upadhyaya, Deepa
Scherrer-Crosbie, Marielle
Okwuosa, Tochukwu M.
Sanghani, Rupa M.
Chalas, Eva
Lindley, Kathryn J.
Dent, Susan
author_sort Parashar, Susmita
collection PubMed
description Improvements in early detection and treatment of gynecologic malignancies have led to an increasing number of survivors who are at risk of long-term cardiac complications from cancer treatment. Multimodality therapies for gynecologic malignancies, including conventional chemotherapy, targeted therapeutics, and hormonal agents, place patients at risk of cancer therapy-related cardiovascular toxicity during and following treatment. Although the cardiotoxicity associated with some female predominant cancers (eg, breast cancer) have been well recognized, there has been less recognition of the potential adverse cardiovascular effects of anticancer therapies used to treat gynecologic malignancies. In this review, the authors provide a comprehensive overview of the cancer therapeutic agents used in gynecologic malignancies, associated cardiovascular toxicities, risk factors for cardiotoxicity, cardiac imaging, and prevention strategies.
format Online
Article
Text
id pubmed-10152205
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-101522052023-05-03 Cancer Treatment-Related Cardiovascular Toxicity in Gynecologic Malignancies: JACC: CardioOncology State-of-the-Art Review Parashar, Susmita Akhter, Nausheen Paplomata, Elisavet Elgendy, Islam Y. Upadhyaya, Deepa Scherrer-Crosbie, Marielle Okwuosa, Tochukwu M. Sanghani, Rupa M. Chalas, Eva Lindley, Kathryn J. Dent, Susan JACC CardioOncol State-of-the-Art Review Improvements in early detection and treatment of gynecologic malignancies have led to an increasing number of survivors who are at risk of long-term cardiac complications from cancer treatment. Multimodality therapies for gynecologic malignancies, including conventional chemotherapy, targeted therapeutics, and hormonal agents, place patients at risk of cancer therapy-related cardiovascular toxicity during and following treatment. Although the cardiotoxicity associated with some female predominant cancers (eg, breast cancer) have been well recognized, there has been less recognition of the potential adverse cardiovascular effects of anticancer therapies used to treat gynecologic malignancies. In this review, the authors provide a comprehensive overview of the cancer therapeutic agents used in gynecologic malignancies, associated cardiovascular toxicities, risk factors for cardiotoxicity, cardiac imaging, and prevention strategies. Elsevier 2023-04-18 /pmc/articles/PMC10152205/ /pubmed/37144116 http://dx.doi.org/10.1016/j.jaccao.2023.02.002 Text en © 2023 Published by Elsevier on behalf of the American College of Cardiology Foundation. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle State-of-the-Art Review
Parashar, Susmita
Akhter, Nausheen
Paplomata, Elisavet
Elgendy, Islam Y.
Upadhyaya, Deepa
Scherrer-Crosbie, Marielle
Okwuosa, Tochukwu M.
Sanghani, Rupa M.
Chalas, Eva
Lindley, Kathryn J.
Dent, Susan
Cancer Treatment-Related Cardiovascular Toxicity in Gynecologic Malignancies: JACC: CardioOncology State-of-the-Art Review
title Cancer Treatment-Related Cardiovascular Toxicity in Gynecologic Malignancies: JACC: CardioOncology State-of-the-Art Review
title_full Cancer Treatment-Related Cardiovascular Toxicity in Gynecologic Malignancies: JACC: CardioOncology State-of-the-Art Review
title_fullStr Cancer Treatment-Related Cardiovascular Toxicity in Gynecologic Malignancies: JACC: CardioOncology State-of-the-Art Review
title_full_unstemmed Cancer Treatment-Related Cardiovascular Toxicity in Gynecologic Malignancies: JACC: CardioOncology State-of-the-Art Review
title_short Cancer Treatment-Related Cardiovascular Toxicity in Gynecologic Malignancies: JACC: CardioOncology State-of-the-Art Review
title_sort cancer treatment-related cardiovascular toxicity in gynecologic malignancies: jacc: cardiooncology state-of-the-art review
topic State-of-the-Art Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152205/
https://www.ncbi.nlm.nih.gov/pubmed/37144116
http://dx.doi.org/10.1016/j.jaccao.2023.02.002
work_keys_str_mv AT parasharsusmita cancertreatmentrelatedcardiovasculartoxicityingynecologicmalignanciesjacccardiooncologystateoftheartreview
AT akhternausheen cancertreatmentrelatedcardiovasculartoxicityingynecologicmalignanciesjacccardiooncologystateoftheartreview
AT paplomataelisavet cancertreatmentrelatedcardiovasculartoxicityingynecologicmalignanciesjacccardiooncologystateoftheartreview
AT elgendyislamy cancertreatmentrelatedcardiovasculartoxicityingynecologicmalignanciesjacccardiooncologystateoftheartreview
AT upadhyayadeepa cancertreatmentrelatedcardiovasculartoxicityingynecologicmalignanciesjacccardiooncologystateoftheartreview
AT scherrercrosbiemarielle cancertreatmentrelatedcardiovasculartoxicityingynecologicmalignanciesjacccardiooncologystateoftheartreview
AT okwuosatochukwum cancertreatmentrelatedcardiovasculartoxicityingynecologicmalignanciesjacccardiooncologystateoftheartreview
AT sanghanirupam cancertreatmentrelatedcardiovasculartoxicityingynecologicmalignanciesjacccardiooncologystateoftheartreview
AT chalaseva cancertreatmentrelatedcardiovasculartoxicityingynecologicmalignanciesjacccardiooncologystateoftheartreview
AT lindleykathrynj cancertreatmentrelatedcardiovasculartoxicityingynecologicmalignanciesjacccardiooncologystateoftheartreview
AT dentsusan cancertreatmentrelatedcardiovasculartoxicityingynecologicmalignanciesjacccardiooncologystateoftheartreview